Howe Christopher R, Gardner Gregory C, Kadel Nancy J
Department of Orthopaedic Surgery, University of Washington School of Medicine, Seattle, WA 98195, USA.
J Am Acad Orthop Surg. 2006 Sep;14(9):544-51. doi: 10.5435/00124635-200609000-00004.
The treatment of rheumatoid arthritis has improved dramatically in recent years with the advent of the latest generation of disease-modifying antirheumatic drugs. Despite these advances, in some patients inflammation is not diminished sufficiently to prevent irreversible musculoskeletal damage, thus requiring surgical intervention to reduce pain and improve function. In these cases, the orthopaedic surgeon frequently encounters patients on a drug regimen consisting of nonsteroidal anti-inflammatory drugs, glucocorticoids, methotrexate, and biologic agents (disease-modifying antirheumatic drugs). Consultation with a rheumatologist is recommended, but the surgeon also should be aware of these medications that could potentially affect surgical outcome. Prudent perioperative management of these drugs is required to optimize surgical outcome. A balance must be struck between minimizing potential surgical complications and maintaining disease control to facilitate postoperative rehabilitation of patients with rheumatoid arthritis.
近年来,随着最新一代改善病情抗风湿药的出现,类风湿关节炎的治疗有了显著改善。尽管有这些进展,但在一些患者中,炎症并未充分减轻以防止不可逆的肌肉骨骼损伤,因此需要手术干预来减轻疼痛并改善功能。在这些情况下,骨科医生经常会遇到正在使用包括非甾体抗炎药、糖皮质激素、甲氨蝶呤和生物制剂(改善病情抗风湿药)的药物治疗方案的患者。建议咨询风湿病学家,但外科医生也应了解这些可能会影响手术结果的药物。需要对这些药物进行谨慎的围手术期管理,以优化手术结果。必须在尽量减少潜在手术并发症和维持疾病控制之间取得平衡,以促进类风湿关节炎患者的术后康复。